Peter Buhl

​

Peter is a serial entrepreneur with broad experience in the life science sector. Originally educated as an MD, DMSc., Peter has a publication list of more than 120 peer reviewed papers on anticancer drug development.

 

Peter is the Founder of TopoTarget A/S 2000, Oncology Venture ApS 2012 and Oncology Venture Sweden AB 2015 (OV.ST),  2X Oncology Inc. 2016

 

As a CEO Peter has built cutting edge pipelines via own development and M&As, listed several companies on the stock exchange, and brought products forward to approval and launch

​

Peter serves on the board of directors of Symbion A/S and Cobis A/S.